Background illustration for clinical trials search

Merck Clinical Trials

Find clinical trials for Merck. Search for Merck clinical trials in different cities and states across the United States.

Filter
Active & Responsive

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

for
Malignant Neoplasm
Location: Quebec, New Brunswick NJ, Montreal, Fairfax VA, Toronto,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07247110

Phase 1, Recruiting
Active & Responsive

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

for
Malignant Neoplasm
Location: Clermont FL, Fargo ND, Sioux Falls SD
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07252739

Phase 2, Recruiting
Active & Responsive

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)

for
Diabetic Retinopathy, Macular Edema
Location: Manchester CT, Bloomfield NJ, Hagerstown MD,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07705555

Phase 3, Recruiting
Active & Responsive

A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)

for
Cytomegalovirus Prophylaxis
Location: The Bronx NY, New York NY, Philadelphia PA, Durham NC,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 0 - 17

Code: NCT07199465

Phase 1, Recruiting
Active & Responsive

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

for
Advanced Solid Tumors
Location: Moncton, Hackensack NJ, Fairfax VA, Kingston, Toronto,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT05067283

Phase 1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

for
Carcinoma, Non-Small-Cell Lung
Location: Lebanon NH, Philadelphia PA, Columbus OH, Houston TX,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT04165798

Recruiting
Active & Responsive

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

for
Colorectal Cancer, Pancreatic Ductal Adenocarcinoma,
Location: Mineola NY, New York NY, Montreal, Ottawa,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06428409

Phase 1, Phase 2, Recruiting
Active & Responsive

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

for
Prostate Cancer, Prostatic Neoplasms
Location: Boston MA, New Haven CT, West Haven CT, New York NY,
Sponsor: Merck Sharp & Dohme LLC

Sex: Male

Age: 18+

Code: NCT06925737

Phase 3, Recruiting
Active & Responsive

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

for
Non-small Cell Lung Cancer, NSCLC
Location: Hackensack NJ, Trois-Rivieres, Pennington NJ, Montreal,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06422143

Phase 3, Recruiting

Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer

for
Triple Negative Breast Cancer
Location: New York NY, Atlanta GA, Maywood IL
Sponsor: Eileen Connolly

Sex: Female

Age: 21 - 70+

Code: NCT02977468

Phase 1, Recruiting
New

A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)

for
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Location: Orlando FL, Fountain Valley CA
Sponsor: Merck Sharp & Dohme LLC

Sex: Female

Age: 18+

Code: NCT07743164

Phase 3, Recruiting
New

A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

for
B-cell Acute Lymphoblastic Leukemia
Location: Toronto
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 12+

Code: NCT07570173

Phase 2, Phase 3, Recruiting
New

A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)

for
Malignant Neoplasm
Location: Iowa City IA
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 12 - 17

Code: NCT07700758

Phase 2, Recruiting
New

A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019)

for
Healthy
Location: Anniston AL
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18 - 65

Code: NCT07595263

Phase 1, Recruiting
New

A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)

for
Advanced Solid Tumors, Malignant Neoplasm
Location: San Antonio TX
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07785609

Phase 2, Recruiting
New

A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)

for
Ovarian Cancer, Ovarian Neoplasms, Peritoneal Cancer,
Location: Washington D.C. DC, Fort Worth TX
Sponsor: Merck Sharp & Dohme LLC

Sex: Female

Age: 18+

Code: NCT07776691

Phase 3, Recruiting
New

A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)

for
Healthy
Location: Marlton NJ, Hollywood FL, South Miami FL, Cleveland OH
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18 - 64

Code: NCT07743151

Phase 1, Recruiting

Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)

for
Invasive Fungal Infection
Location: Chicago IL
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 0 - 2

Code: NCT04665037

Phase 2, Recruiting

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

for
Small Cell Lung Cancer
Location: Boston MA, Hackensack NJ, Miami FL, Buffalo NY,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06780137

Phase 1, Phase 2, Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

for
Non Small Cell Lung Cancer
Location: Westbrook ME, Stony Brook NY, Stamford CT,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06312137

Phase 3, Recruiting